Development of Medical Countermeasures for Biodefense and Emerging Diseases
$4,996,104N01FY2013AINIH
Biocryst Pharmaceuticals, Inc., Birmingham AL
Investigators
Abstract
This contract supports the advanced development of promising therapeutic candidates with broad spectrum activity. The research and development activities to be supported will allow candidate therapeutic products to progress through the product development pipeline, and includes preclinical and non-clinical activities, as well as IND development activities.
View original record on NIH RePORTER →